Physicians' Academy for Cardiovascular Education

Teaming up to tackle cardiorenal risk in diabetes - Role of SGLT2i: How to overcome clinical inertia

This accredited symposium " Teaming up to tackle cardiorenal risk in diabetes - Role of SGLT2i: How to overcome clinical inertia" was held during the virtual EASD 2021 and consists of three educational videos.

E-learning Teaming up to tackle cardiorenal risk in diabetes

Accredited e-Learning

Online-CME - This course consists of 3 parts.
This course consists of 3 parts.

Managing patients with diabetes requires a team approach of physicians in primary care, nephrologists, cardiologists and diabetologists. In this e-learning course, the discussants present a case of a patient with diabetes and comorbidities that shows the complexity of management of such a patient.

Symposium on the role of SGLT2i in tackling cardiorenal risk in diabetes

15' education - Oct. 28, 2021 - Prof. Melanie Davies, MD and prof. Nikolaus Marx, MD - Online CME
Watch the entire symposium on teaming up to tackle cardiorenal risk in diabetes - The role of SGLT2i: How to overcome clinical inertia?

Watch the entire symposium on teaming up to tackle cardiorenal risk in diabetes - The role of SGLT2i: How to overcome clinical inertia?

Dialogue on how to overcome clinical inertia with regard to SGLT2i

Lecture 3 out of 3

10' education - Oct. 28, 2021 - Prof. Melanie Davies, MD and prof. Nikolaus Marx, MD - Online CME
As part of a series on tackling cardiorenal risk in diabetes, prof. Davies and prof. Marx state that current use of SGLT2 inhibitors is low and discuss how to overcome this.

As part of a series on tackling cardiorenal risk in diabetes, prof. Davies and prof. Marx state that current use of SGLT2 inhibitors is low and discuss how to overcome this.

SGLT2i: Overview of recent trials and guideline recommendations

Lecture 2 out of 3

10' education - Oct. 28, 2021 - Prof. Nikolaus Marx, MD - Online CME
This presentation by prof. Marx is the second part of a series on tackling cardiorenal risk in patients with diabetes. He provides an overview of clinical trials with SGLT2 inhibitors and current recommendations in guidelines.

This presentation by prof. Marx is the second part of a series on tackling cardiorenal risk in patients with diabetes. He provides an overview of clinical trials with SGLT2 inhibitors and current recommendations in guidelines.

Introduction on tackling cardiorenal risk in diabetes

Lecture 1 out of 3

10' education - Oct. 28, 2021 - Prof. Melanie Davies, MD - Online CME
Watch the first part of a series on tackling cardiorenal risk in patients with diabetes by teaming up. Prof. Davies introduces the topic and presents a case.

Watch the first part of a series on tackling cardiorenal risk in patients with diabetes by teaming up. Prof. Davies introduces the topic and presents a case.

Teaming up to tackle cardiorenal risk in diabetes -  Role of SGLT2i: How to overcome clinical inertia